|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
1 | AN ACT concerning public health.
| ||||||||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| ||||||||||||||||||||||||
3 | represented in the General Assembly:
| ||||||||||||||||||||||||
4 | Section 1. Short title. This Act may be cited as the Lupus | ||||||||||||||||||||||||
5 | Education and Awareness Act. | ||||||||||||||||||||||||
6 | Section 5. Legislative findings and purpose. | ||||||||||||||||||||||||
7 | (a) The General Assembly finds the following: | ||||||||||||||||||||||||
8 | (1) Lupus is an urgent national health issue. Lupus is | ||||||||||||||||||||||||
9 | the result of an immune system that is unbalanced and can | ||||||||||||||||||||||||
10 | become destructive to any organ or tissue in the body. | ||||||||||||||||||||||||
11 | Lupus is unpredictable and potentially fatal, yet no | ||||||||||||||||||||||||
12 | satisfactory treatment exists. Its health consequences | ||||||||||||||||||||||||
13 | include heart attacks, strokes, seizures, and organ | ||||||||||||||||||||||||
14 | failure. | ||||||||||||||||||||||||
15 | (2) The Lupus Foundation of America, Inc. estimates | ||||||||||||||||||||||||
16 | that more than 1.5 million Americans live with some form of | ||||||||||||||||||||||||
17 | lupus; lupus affects women 9 times more often than men, and | ||||||||||||||||||||||||
18 | 80% of newly diagnosed cases of lupus develop among women | ||||||||||||||||||||||||
19 | of childbearing age. An estimated 65,000 people with lupus | ||||||||||||||||||||||||
20 | reside in Illinois. | ||||||||||||||||||||||||
21 | (3) Lupus disproportionately affects women of color; | ||||||||||||||||||||||||
22 | it is 2 to 3 times more common among African Americans, | ||||||||||||||||||||||||
23 | Hispanics and Latinos, Asians, and Native Americans and is |
| |||||||
| |||||||
1 | generally more prevalent in minority populations, a health | ||||||
2 | disparity that remains unexplained. | ||||||
3 | (4) No new drugs have been approved by the U.S. Food | ||||||
4 | and Drug Administration specifically for lupus in 50 years | ||||||
5 | and, while current treatments for the disease can be | ||||||
6 | effective, they can lead to damaging side effects. | ||||||
7 | (5) The pain and fatigue associated with lupus can | ||||||
8 | threaten one's ability to live independently, make it | ||||||
9 | difficult to maintain employment, and lead normal lives. | ||||||
10 | One in 5 people with lupus is disabled by the disease and | ||||||
11 | consequently receives support from government programs, | ||||||
12 | including Medicare, Medicaid, Social Security Disability, | ||||||
13 | and Social Security Supplemental Income. | ||||||
14 | (6) The estimated average annual total of direct and | ||||||
15 | indirect costs for an individual with lupus is $21,000; for | ||||||
16 | people who have the most serious form of lupus, medical | ||||||
17 | costs can greatly exceed this amount, causing a significant | ||||||
18 | economic, emotional, and social burden to the entire family | ||||||
19 | and society. | ||||||
20 | (b) The purpose of this Act is to create a multi-pronged, | ||||||
21 | statewide program to promote public and health professional | ||||||
22 | awareness among State and local health and human services | ||||||
23 | officials, physicians, nurses, and other health care providers | ||||||
24 | and increase knowledge concerning the causes and consequences | ||||||
25 | of lupus, the importance of early diagnosis and appropriate | ||||||
26 | management, and effective treatment and management strategies |
| |||||||
| |||||||
1 | by taking the following actions: | ||||||
2 | (1) Conducting educational and training programs for | ||||||
3 | health professionals on lupus diagnosis and management.
| ||||||
4 | (2) Disseminating medically sound educational | ||||||
5 | materials and information on lupus research findings to | ||||||
6 | patients and health care professionals.
| ||||||
7 | (3) Fostering greater public understanding and | ||||||
8 | awareness of lupus statewide.
| ||||||
9 | Section 10. Definitions. For the purpose of this Act: | ||||||
10 | "Department" means the Department of Public Health. | ||||||
11 | "Director" means the Director of Public Health. | ||||||
12 | "Panel" means the Interagency and Partnership Advisory | ||||||
13 | Panel on Lupus. | ||||||
14 | "Program" means the Lupus Education and Awareness Program | ||||||
15 | (LEAP).
| ||||||
16 | Section 15. Establishment of the Lupus Education and | ||||||
17 | Awareness Program.
| ||||||
18 | (a) There is created within the Department of Public Health | ||||||
19 | the Lupus Education and Awareness Program (LEAP). The Program | ||||||
20 | shall be composed of various components, including, but not | ||||||
21 | limited to, public awareness activities and professional | ||||||
22 | education programs. The Interagency and Partnership Advisory | ||||||
23 | Panel on Lupus is created to oversee LEAP and advise the | ||||||
24 | Department in implementing LEAP. |
| |||||||
| |||||||
1 | (b) The Department shall establish, promote, and maintain | ||||||
2 | the Lupus Education and Awareness Program with an emphasis on | ||||||
3 | minority populations and at-risk communities in order to raise | ||||||
4 | public awareness, educate consumers, and educate and train | ||||||
5 | health professionals, human service providers, and other | ||||||
6 | audiences. | ||||||
7 | The Department shall work with the Lupus Foundation of | ||||||
8 | America, Inc. to implement programs to raise public awareness | ||||||
9 | about the symptoms and nature of lupus, personal risk factors, | ||||||
10 | and options for diagnosing and treating the disease, with a | ||||||
11 | particular focus on populations at elevated risk for lupus, | ||||||
12 | including women and communities of color. | ||||||
13 | The Program shall include initiatives to educate and train | ||||||
14 | physicians, health care professionals, and other service | ||||||
15 | providers on the most up-to-date and accurate scientific and | ||||||
16 | medical information regarding lupus diagnosis, treatment, | ||||||
17 | risks and benefits of medications, research advances, and | ||||||
18 | therapeutic decision making, including medical best practices | ||||||
19 | for detecting and treating the disease in special populations. | ||||||
20 | These activities shall include, but not be limited to, all of | ||||||
21 | the following: | ||||||
22 | (1) Distribution of medically-sound health information | ||||||
23 | produced by the Lupus Foundation of America, Inc. and | ||||||
24 | government agencies, including, but not limited to, the | ||||||
25 | National Institutes of Health, the Centers for Disease | ||||||
26 | Control and Prevention, and the Social Security |
| |||||||
| |||||||
1 | Administration, through local health departments, schools, | ||||||
2 | agencies on aging, employer wellness programs, physicians | ||||||
3 | and other health professionals, hospitals, health plans | ||||||
4 | and health maintenance organizations, women's health | ||||||
5 | programs, and nonprofit and community-based organizations. | ||||||
6 | (2) Development of educational materials for health | ||||||
7 | professionals that identify the latest scientific and | ||||||
8 | medical information and clinical applications. | ||||||
9 | (3) Working to increase knowledge among physicians, | ||||||
10 | nurses, and health and human services professionals about | ||||||
11 | the importance of lupus diagnosis, treatment, and | ||||||
12 | rehabilitation.
| ||||||
13 | (4) Support of continuing medical education programs | ||||||
14 | presented by the leading State academic institutions by | ||||||
15 | providing them with the most up-to-date information.
| ||||||
16 | (5) Providing statewide workshops and seminars for | ||||||
17 | in-depth professional development regarding the care and | ||||||
18 | management of patients with lupus in order to bring the | ||||||
19 | latest information on clinical advances to care providers.
| ||||||
20 | (6) Development and maintenance of a directory of | ||||||
21 | lupus-related services and lupus health care providers | ||||||
22 | with specialization in services to diagnose and treat | ||||||
23 | lupus. The Department shall disseminate this directory to | ||||||
24 | all stakeholders, including, but not limited to, | ||||||
25 | individuals with lupus, families, and representatives from | ||||||
26 | voluntary organizations, health care professionals, health |
| |||||||
| |||||||
1 | plans, and State and local health agencies. | ||||||
2 | (c) The Director shall do all of the following: | ||||||
3 | (1) Designate a person in the Department to oversee the | ||||||
4 | Program.
| ||||||
5 | (2) Identify the appropriate entities to carry out the | ||||||
6 | Program, including, but not limited to, the following: | ||||||
7 | local health departments, schools, agencies on aging, | ||||||
8 | employer wellness programs, physicians and other health | ||||||
9 | professionals, hospitals, health plans and health | ||||||
10 | maintenance organizations, women's health organizations, | ||||||
11 | and nonprofit and community-based organizations.
| ||||||
12 | (3) Base the Program on the most current scientific | ||||||
13 | information and findings.
| ||||||
14 | (4) Work with governmental entities, community and | ||||||
15 | business leaders, community organizations, health care and | ||||||
16 | human service providers, and national, State, and local | ||||||
17 | organizations to coordinate efforts to maximize State | ||||||
18 | resources in the areas of lupus education and awareness.
| ||||||
19 | (5) Use public health institutions for dissemination | ||||||
20 | of medically sound health materials.
| ||||||
21 | (d) The Department shall establish and coordinate the | ||||||
22 | Interagency and Partnership Advisory Panel on Lupus consisting | ||||||
23 | of 15 members, one of whom shall be appointed by the Director | ||||||
24 | as the chair.
The Panel shall be composed of: | ||||||
25 | (1) at least 3 individuals with lupus;
| ||||||
26 | (2) three representatives from relevant State agencies |
| |||||||
| |||||||
1 | including the Department;
| ||||||
2 | (3) three scientists with experience in lupus who | ||||||
3 | participate in various fields of scientific endeavor, | ||||||
4 | including, but not limited to, biomedical research, | ||||||
5 | social, translational, behavioral, and epidemiological | ||||||
6 | research, and public health;
| ||||||
7 | (4) two medical clinicians with experience in treating | ||||||
8 | people with lupus; and
| ||||||
9 | (5) four representatives from relevant nonprofit | ||||||
10 | women's and health organizations, including one | ||||||
11 | representative from the Lupus Foundation of America, Inc. | ||||||
12 | Individuals and organizations may submit nominations to | ||||||
13 | the Director to be named to the Panel. Such nominations may | ||||||
14 | include the following: | ||||||
15 | (i) representatives from appropriate State departments | ||||||
16 | and agencies, such as entities with responsibility for | ||||||
17 | health disparities, public health programs, education, | ||||||
18 | public welfare, and women's health programs; | ||||||
19 | (ii) health and medical professionals with expertise | ||||||
20 | in lupus; and | ||||||
21 | (iii) individuals with lupus, and recognized experts | ||||||
22 | in the provision of health services to women, lupus | ||||||
23 | research, or health disparities. | ||||||
24 | All members of the panel shall serve terms of 2 years. A | ||||||
25 | member may be appointed to serve not more than 2 terms, whether | ||||||
26 | or not consecutive.
A majority of the members of the panel |
| |||||||
| |||||||
1 | shall constitute a quorum. A majority vote of a quorum shall be | ||||||
2 | required for any official action of the Panel.
The Panel shall | ||||||
3 | meet at the call of the chair, but not less than 2 times per | ||||||
4 | year. All members shall serve without compensation, but shall | ||||||
5 | be entitled to actual, necessary expenses incurred in the | ||||||
6 | performance of their business as members of the Panel in | ||||||
7 | accordance with the reimbursement polices for the State. | ||||||
8 | Section 20. Funding. Subject to the availability of funds, | ||||||
9 | the Department may make expenditures of up to $2,500 for Fiscal | ||||||
10 | year 2010 for use toward providing educational materials to | ||||||
11 | clinics serving a high percentage of minorities in this State. | ||||||
12 | The Director may accept grants, services, and property from the | ||||||
13 | federal government, foundations, organizations, medical | ||||||
14 | schools, and other entities as may be available for the | ||||||
15 | purposes of fulfilling the obligations of this Program. Any | ||||||
16 | such funds shall only supplement any appropriations made for | ||||||
17 | the implementation of this Act. The Director shall seek any | ||||||
18 | federal waiver or waivers that may be necessary to maximize | ||||||
19 | funds from the federal government to implement the Program.
|